{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:26:43Z","timestamp":1792099603051,"version":"4.4.0"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"\n Importance<\/jats:title>\n Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by severe pruritus and nodule formation, significantly affecting patients\u2019 quality of life. There is an unmet need for effective therapies to address both symptoms and disease progression.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the efficacy, safety, tolerability, and pharmacokinetics of monthly dosed vixarelimab in participants with moderate to severe PN.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This double-blind (DB), placebo-controlled, phase 2b randomized clinical trial was conducted from December 1, 2020, to August 24, 2023, across 72 centers in the US, Canada, Europe, and Asia. The study included male and female participants aged 18 to 80 years with physician-diagnosed PN of at least 6 months\u2019 duration and moderate to severe pruritus. Data were analyzed from October 2023 to March 2024.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants were randomized into 4 arms during the 16-week DB period: vixarelimab, 540 mg (high-dose group); vixarelimab, 360 mg (mid-dose group); vixarelimab, 120 mg (low-dose group); or placebo. Vixarelimab and placebo were administered subcutaneously every 4 weeks. During the 36-week open-label extension, all participants received vixarelimab, 360 mg, every 2 weeks.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Key outcomes included percentage change from baseline in the Worst Itch Numeric Rating Scale (WI-NRS) at week 16, the proportion of participants achieving at least a 4-point reduction in WI-NRS at week 16, and the proportion achieving scores of 0 or 1 in the PN Investigator Global Assessment at week 16.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 190 randomized participants, 189 received 1 or more doses of the study drug (141 vixarelimab, 48 placebo). A total of 114 (60.3%) were female, 75 (39.7%) were male, and the mean (SD) age was 55.4 (13.8) years. There were 47 participants in the high-dose vixarelimab group, 47 in the mid-dose group, 47 in the low-dose group, and 48 in the placebo group. Vixarelimab significantly reduced mean (SE) WI-NRS scores at week 16 compared with placebo across all doses (vixarelimab at high-dose, mid-dose, and low-dose levels: \u221256.2% [4.84], \u221251.0% [4.83], and \u221233.0% [4.86], respectively; placebo, \u221214.5% [4.76]). Clinically meaningful 4-point or greater reductions in WI-NRS were achieved by 31 (66.0%), 29 (61.7%), and 14 (29.8%) in the high-dose, mid-dose, and low-dose vixarelimab groups, respectively, compared with 8 (16.7%) in the placebo group. PN Investigator Global Assessment scores of 0 or 1 were also higher in vixarelimab groups (high-dose group, 18 [38.3%]; mid-dose group, 14 [29.8%]; low-dose group, 7 [14.9%]; placebo group, 5 [10.4%]). No fatal or serious drug-related treatment-emergent adverse events were reported during the study, and no serious treatment-related treatment-emergent adverse events were observed during the DB period.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this phase 2b randomized clinical trial, vixarelimab demonstrated rapid, sustained, dose-dependent clinical benefits in patients with PN, with a favorable safety profile.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT03816891<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2025.4950","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T16:00:38Z","timestamp":1765987238000},"page":"133","source":"Crossref","is-referenced-by-count":14,"title":["Vixarelimab in Patients With Prurigo Nodularis"],"prefix":"10.1001","volume":"162","author":[{"given":"Sonja","family":"St\u00e4nder","sequence":"first","affiliation":[{"name":"Section for Pruritus Medicine, Department of Dermatology, M\u00fcnster University Hospital, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Yosipovitch","sequence":"additional","affiliation":[{"name":"University of Miami Miller School of Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Sofen","sequence":"additional","affiliation":[{"name":"UCLA School of Medicine, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Abramzon","sequence":"additional","affiliation":[{"name":"Genentech Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Galanter","sequence":"additional","affiliation":[{"name":"Genentech Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheldon","family":"Wang","sequence":"additional","affiliation":[{"name":"Kiniksa Pharmaceuticals, Lexington, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Paolini","sequence":"additional","affiliation":[{"name":"Kiniksa Pharmaceuticals, Lexington, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"doi250060r1","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1111\/jdv.15107","article-title":"Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need.","volume":"32","author":"Pereira","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"doi250060r2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2340\/00015555-2774","article-title":"Chronic prurigo of nodular type: a review.","volume":"98","author":"Zeidler","year":"2018","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"doi250060r3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3390\/medicines6040097","article-title":"Diagnostic workup and evaluation of patients with prurigo nodularis.","volume":"6","author":"Kwon","year":"2019","journal-title":"Medicines (Basel)"},{"issue":"1","key":"doi250060r4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/17512433.2021.1852080","article-title":"Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis.","volume":"14","author":"Williams","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"doi250060r5","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jaad.2020.07.025","article-title":"Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus.","volume":"84","author":"Elmariah","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi250060r6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaad.2018.04.044","article-title":"Humanistic burden of chronic pruritus in patients with inflammatory dermatoses: results of the European Academy of Dermatology and Venereology Network on Assessment of Severity and Burden of Pruritus (PruNet) cross-sectional trial.","volume":"79","author":"Steinke","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi250060r7","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.37765\/ajmc.2023.89366","article-title":"A review of the current management and burden of prurigo nodularis in the United States.","volume":"29","author":"Chisolm","year":"2023","journal-title":"Am J Manag Care"},{"key":"doi250060r8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jdin.2020.10.009","article-title":"Prevalence of prurigo nodularis in the United States of America: a retrospective database analysis.","volume":"2","author":"St\u00e4nder","year":"2020","journal-title":"JAAD Int"},{"issue":"2","key":"doi250060r9","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jid.2019.07.697","article-title":"Real-world prevalence of prurigo nodularis and burden of associated diseases.","volume":"140","author":"Huang","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"1","key":"doi250060r10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/jdv.15145","article-title":"The self-assessed psychological comorbidities of prurigo in European patients: a multicentre study in 13 countries.","volume":"33","author":"Brenaut","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"doi250060r11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3390\/vaccines9030303","article-title":"Pruritus as a distinctive feature of type 2 inflammation.","volume":"9","author":"Garcovich","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"8","key":"doi250060r12","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00403-020-02148-0","article-title":"The impact of prurigo nodularis on quality of life: a systematic review and meta-analysis.","volume":"313","author":"Janmohamed","year":"2021","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"doi250060r13","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1111\/jdv.13827","article-title":"Anxiety, depression and suicide in patients with prurigo nodularis.","volume":"31","author":"J\u00f8rgensen","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"doi250060r14","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.jaad.2018.09.020","article-title":"A systematic review of evidence-based treatments for prurigo nodularis.","volume":"80","author":"Qureshi","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"doi250060r15","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1111\/jdv.20099","article-title":"Responder analysis using clinically meaningful thresholds: post hoc analyses from randomized dupilumab clinical trials in patients with prurigo nodularis.","volume":"38","author":"Kwatra","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"doi250060r16","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jaci.2017.10.045","article-title":"IL-31: a new key player in dermatology and beyond.","volume":"141","author":"Bagci","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"14","key":"doi250060r17","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3505","article-title":"Oncostatin M induction of monocyte chemoattractant protein 1 is inhibited by anti-oncostatin M receptor beta monoclonal antibody KPL-716.","volume":"100","author":"Richards","year":"2020","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"doi250060r18","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/exd.14279","article-title":"Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta.","volume":"30","author":"Hashimoto","year":"2021","journal-title":"Exp Dermatol"},{"issue":"1","key":"doi250060r19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jaci.2019.08.013","article-title":"Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus.","volume":"145","author":"Silverberg","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"doi250060r20","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa1908316","article-title":"Trial of nemolizumab in moderate-to-severe prurigo nodularis.","volume":"382","author":"St\u00e4nder","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"doi250060r21","doi-asserted-by":"publisher","DOI":"10.1111\/exd.15115","article-title":"IL-4 and IL-13 are not involved in IL-31-induced itch-associated scratching behaviour in mice.","volume":"33","author":"Kawai","year":"2024","journal-title":"Exp Dermatol"},{"issue":"1","key":"doi250060r22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/jcb.25246","article-title":"The leukemia inhibitory factor receptor gene is a direct target of RUNX1.","volume":"117","author":"Qadi","year":"2016","journal-title":"J Cell Biochem"},{"issue":"5","key":"doi250060r23","doi-asserted-by":"publisher","first-page":"S96","DOI":"10.1016\/j.jid.2019.03.636","article-title":"560 KPL-716, anti-oncostatin M receptor beta antibody, reduced pruritus in atopic dermatitis.","volume":"139","author":"Mikhak","year":"2019","journal-title":"J Invest Dermatol"},{"key":"doi250060r24","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101826","article-title":"Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor \u00df antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study.","volume":"57","author":"Sofen","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"2","key":"doi250060r25","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3701","article-title":"Investigator\u2019s Global Assessment of Chronic Prurigo: a new instrument for use in clinical trials.","volume":"101","author":"Zeidler","year":"2021","journal-title":"Acta Derm Venereol"},{"issue":"17","key":"doi250060r26","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1056\/NEJMoa2301333","article-title":"Phase 3 trial of nemolizumab in patients with prurigo nodularis.","volume":"389","author":"Kwatra","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"doi250060r27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jamadermatol.2024.4796","article-title":"Efficacy and safety of nemolizumab in patients with moderate to severe prurigo nodularis: the OLYMPIA 1 randomized clinical phase 3 trial.","volume":"161","author":"St\u00e4nder","year":"2025","journal-title":"JAMA Dermatol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2842471\/jamadermatology_stnder_2025_oi_250060_1770869589.67993.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T16:00:29Z","timestamp":1771430429000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2842471"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2025.4950","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,1]]}}}